Nivolumab plus platinum-doublet chemotherapy as first-line therapy in unresectable, locally advanced or metastatic G3 neuroendocrine Neoplasms (NENs) of the gastroenteropancreatic (GEP) tract or unknown (UK) origin: Preliminary results from the phase II NICE-NEC trial (GETNE T1913)

Riesco-Martinez, M. C.Capdevila, J.Alonso, V.Jimenez-Fonseca, P.Teule, A.Grande, E.Sevilla, I.Benavent Vinuales, M.Alonso-Gordoa, T.Custodio, A.Hernando, J.Polo, E.Castillo Trujillo, O. A.Garcia-Carbonero, R.2025-01-072025-01-072021-09-210923-7534https://hdl.handle.net/10668/27026enNivolumab plus platinum-doublet chemotherapy as first-line therapy in unresectable, locally advanced or metastatic G3 neuroendocrine Neoplasms (NENs) of the gastroenteropancreatic (GEP) tract or unknown (UK) origin: Preliminary results from the phase II NICE-NEC trial (GETNE T1913)conference outputopen access10.1016/j.annonc.2021.08.1801569-8041https://doi.org/10.1016/j.annonc.2021.08.180700527702116